Ligand-based CAR-T cell: Different strategies to drive T cells in future new treatments
Authors:
Open Access
- 12 September 2022
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 13, 932559
Abstract
Chimeric antigen receptor (CAR)-based therapies are presented as innovative treatments for multiple malignancies. Despite their clinical success, there is scientific evidence of the limitations of these therapies mainly due to immunogenicity issues, toxicities associated with the infusion of the product, and relapses of the tumor. As a result, novel approaches are appearing aiming to solve and/or mitigate the harmful effects of CAR-T therapies. These include strategies based on the use of ligands as binding moieties or ligand-based CAR-T cells. Several proposals are currently under development, with some undergoing clinical trials to assess their potential benefits. In addition to these, therapies such as chimeric autoantibody receptor (CAAR), B-cell receptor antigen for reverse targeting (BAR), and even chimeric human leukocyte antigen (HLA) antibody receptor (CHAR) have emerged, benefiting from the advantages of antigenic ligands as antibody-binding motifs. This review focuses on the potential role that ligands can play in current and future antitumor treatments and in other types of diseases, such as autoimmune diseases or problems associated with transplantation.Keywords
This publication has 106 references indexed in Scilit:
- Incidence and Clinical Significance ofDe NovoDonor Specific Antibodies after Kidney TransplantationJournal of Immunology Research, 2013
- Stem-like Tumor-Initiating Cells Isolated from IL13Rα2 Expressing Gliomas Are Targeted and Killed by IL13-Zetakine–Redirected T CellsClinical Cancer Research, 2012
- scFv Antibody: Principles and Clinical ApplicationJournal of Immunology Research, 2012
- Silencing IL-13Rα2 Promotes Glioblastoma Cell Death via Endogenous SignalingMolecular Cancer Therapeutics, 2011
- T cells redirected against CD70 for the immunotherapy of CD70-positive malignanciesBlood, 2011
- Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinaseProceedings of the National Academy of Sciences of the United States of America, 2011
- Selective Expansion of Chimeric Antigen Receptor-targeted T-cells with Potent Effector Function using Interleukin-4Journal of Biological Chemistry, 2010
- Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2Molecular Therapy, 2010
- Improved survival in multiple myeloma and the impact of novel therapiesBlood, 2008
- The ErbB signaling network: receptor heterodimerization in development and cancerThe EMBO Journal, 2000